07/09/2009
Molecular LogiX awarded patent for novel targeted therapeutic aimed at all HER positive cancers.


09/19/2008
Opexa Announces Top-Line Results from Phase IIb Clinical Trial of Tovaxin® for the Treatment of Multiple Sclerosis
Tovaxin Shows Favorable Annualized Relapse Rate and Excellent Safety Profile


09/11/2008
Top-Line Data from Opexa’s Phase IIb Tovaxin® Study to be Presented at World Congress on Treatment and Research in Multiple Sclerosis
Novel T-Cell Vaccine Being Evaluated as Patient-Specific Treatment for MS


09/03/2008
Opexa Therapeutics and Myelin Repair Foundation Partner on Novel Multiple Sclerosis Research Program
Collaboration to Identify Therapeutically Relevant Biomarkers and Offer Key Insight for Further Clinical Development of Tovaxin®


08/20/2008
Fairway Medical Technology to Develop BioSensor for Blood Pathogens and Warfare Threats

Navy contract aims for real-time laboratory-quality capabilities in rugged battlefield instrument


08/19/2008
Kryptiq Acquires Secure Network Solutions
Automatic Appointment Reminders and Billing Statements Strengthen Connect IQ™ Platform


08/14/2008
Opexa Therapeutics Reports Second Quarter 2008 Financial Results and Recent Corporate Highlights
Conference Call Scheduled for August 19, 2008, at 4:00 p.m. Eastern Time


08/13/2008
Opexa Therapeutics Completes $3 Million Financing
Funding to Support Ongoing Clinical Development of Tovaxin®


07/22/2008
Opexa Conducts Additional Analysis on Phase I/II Extension Study with Tovaxin® for Multiple Sclerosis
Annual treatments with patient specific vaccine appear beneficial


07/08/2008
Opexa’s Phase IIb Study of Tovaxin® Receives Positive Review from Data Safety Monitoring Board


07/01/2008
Results Published in the Journal Cancer Demonstrate That Oral Talactoferrin Alfa Is Active As Monotherapy In Previously Treated Patients With Metastatic Renal Cell Carcinom


06/18/2008
Kryptiq’s Choreo Suite Brings Automation and ROI to CareSource Management Group
Ohio’s Largest Medicaid Managed Care Plan Experiences Savings of More Than $10,000 for Every 500 Contracts Created


06/17/2008
Northwest Permanente Implements Kryptiq’s Choreo Contract Manager
Nation’s Largest Nonprofit Health Plan Standardizes Language of Contracts


06/17/2008
Opexa Therapeutics Appoints Neil K. Warma President and CEO


06/16/2008
Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at the International Society for Stem Cell Research Annual Meeting
Insulin signaling pathways identified in monocyte-derived islets


06/12/2008
Opexa Therapeutics Reports Favorable Two-Year Data in Phase I/II Retreatment Studies of Tovaxin® for Multiple Sclerosis
73% of patients remained relapse-free at two years


06/10/2008
Kryptiq Launches First Solution for Connectivity Between Clinical Environment and Microsoft HealthVault
GreenField Health Utilizes Connect IQ™ Patient Portal to Give Patients More Control Over Health Data


06/09/2008
CSC ADDS PROVIDER CONTRACTING TO HOSTED HEALTHCARE OFFERING
Kryptiq’s Choreo Suite Available to Healthcare Organizations through CSC’s FirstPortfolio


05/29/2008
GE Healthcare IT Announces ePrescribing for Centricity EMR
GE Healthcare and Kryptiq collaborate in joint development partnership


05/22/2008
Opexa Therapeutics Presents Myelin Reactive T-Cell Research at the International Society of Cell Therapy Annual Meeting


05/15/2008
The Portland Business Journal Honors Kryptiq’s Kurt Koehler with CFO of the Year Award
Award Recognizes Outstanding Performance to Company Growth, Industry Leadership and Contributions to the Community


05/14/2008
Opexa Therapeutics Schedules First Quarter Results Conference Call; May 21, 2008 at 4:00 p.m. Eastern Tim


05/13/2008
Opexa Therapeutics Reports First Quarter 2008 Financial Results and Updates on Tovaxin® Phase IIb Study


04/22/2008
Agennix Initiates a Randomized Double-Blind, Placebo-Controlled Phase 2 Study Of Oral Talactoferrin in Severe Sepsis

Company also announces Award of a National Institutes of Health Small Business Innovative Research (SBIR) Grant to support the Phase 2 Trial


04/17/2008
Medford Medical Clinic Writes a Prescription for Change: Kryptiq’s eScriptMessenger
Oregon-based Medical Clinic Joins National Move to ePrescribing, Improving Patient Safety and Quality of Care


04/15/2008
Opexa Therapeutics Presents Tovaxin Phase I/II Data at the American Academy of Neurology 60th Annual Meeting


03/26/2008
Opexa Therapeutics’ Form 10-K Report Audit Includes 'Going Concern' Qualific


03/24/2008
Opexa Therapeutics to Present at the Cambria Capital Investor Meeting


03/21/2008
Opexa Therapeutics Announces Retirement of CEO David McWilliams
Search Underway for Successor


03/18/2008
Opexa Therapeutics Reports Year End 2007 Financial Results
Conference Call Scheduled for March 25th at 4:00 p.m. Eastern Time


03/13/2008
Boston Medical Center Meets Prescription Challenges with Kryptiq ePrescribing Solution
Kryptiq’s eScriptMessenger Eases Compliance with Upcoming Federal Mandates


03/11/2008
Opexa Therapeutics Announces Completion of Mid Study Descriptive Analysis on Phase IIb Trial of Tovaxin® for Treatment of Multiple Sclerosis
Data Safety Monitoring Board Recommends Continuing Trial as Scheduled


02/26/2008
Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at The 8th Annual Targeted Therapies For The Treatment Of Lung Cancer Meeting

Company Also Announces Receipt of Fast Track Designation from FDA, Favorable Scientific Advice from EMEA and Phase 3 Plans for the Non-Small Cell Lung Cancer Monotherapy Indication


02/25/2008
Kryptiq Customer Receives HIMSS Nicholas E. Davies Award of Excellence
Village Health Partners Powers Award-Winning Care and Service with Patient Portal


02/25/2008
Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS ‘08
Connect IQ for HealthVault Empowers Patients to Orchestrate Health Information Mobility


02/21/2008
Hillsboro Advanced Surgical Care Extends Value of EMR with Connect IQ Secure Messaging
Kryptiq enables Medical Practice to Accelerate Revenue Cycle


02/21/2008
Frederick Primary Care Associates Partners with Kryptiq for Patient Online Services
Connect IQ Integrates Practice Web site with Allscripts EMR and PM



02/19/2008
Regence Automates Provider Contracting with Kryptiq’s Choreo Contract Manager
Blues Plan Creates 27,000 Contracts and Amendments with Industry Leading Solution


02/19/2008
Opexa Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Series E Warrant


02/14/2008
Providence Health & Services – Oregon Region Powers Consumer Portal with Kryptiq Connect IQ
Providence Hospitals and Medical Clinics Connect on Common Secure Messaging Platform


02/13/2008
Opexa Therapeutics Announces the Pricing of Public Offering of Shares of Common Stock and Series E Warrant


02/12/2008
Sapphire Therapeutics Promotes Suzan Allen to Vice President Clinical Operation


01/31/2008
CoxHealth Deploys Kryptiq ePrescribing Solution
Kryptiq’s eScriptMessenger Enables Improved Patient Safety and Office Efficiency


01/17/2008
Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer

Trial will also Support a Marketing Authorization Application in the European Union


12/11/2007
Kryptiq Recognized for Second Consecutive Year as an Oregon Most Admired Company
Healthcare Technology Leader Honored as One of the State’s Top Five Technology Companies


11/29/2007
Kryptiq’s Connect IQ Drives Practice Efficiency and Patient Friendly Experience
Physicians Report Online Collaboration Saves 20 Percent of Time Spent by Medical Assistants on Manual Tasks


11/28/2007
Speaker Nancy Pelosi Learns How Secure Messaging is Transforming Healthcare
Kryptiq CEO Luis Machuca Shows Connect IQ™ Success to HIT Roundtable, including Congressmen David Wu and Governor Ted Kulongoski


11/16/2007
Opexa Therapeutics’ Amendment No.1 on Form 10-KSB/A Report Audit Includes 'Going Concern' Qualific


11/13/2007
Fairway Receives $1.4 Million for Phase II Research Grant - 3D Hybrid Opto-acoustics-Ultrasonic System for Diagnostic Imaging of Breast Cancer


11/05/2007
Opexa Reports Third Quarter 2007 Financial Result


11/01/2007
Popper named president of BCM Technologies Inc.


11/01/2007
Rocky Mountain Health Plans Transforms Provider Contracting Processes with Kryptiq’s Choreo Suite
#1 Provider Contract Management Suite Simplifies Contract Creation, Negotiation, and Distribution


10/30/2007
Sapphire Therapeutics Licenses Ghrelin Antagonist Program from Novo Nordisk for Development of Obesity Treatment


10/11/2007
MedStar Health to Transform Care Collaboration with Kryptiq’s CareManager and Connect IQ Suite
Largest Health System in Baltimore/Washington Licenses Kryptiq’s Solutions to Improve Patient Service and Quality of Care


10/05/2007
Opexa Therapeutics to Present at the BIO Investor Forum 200


10/04/2007
Kryptiq Provides Secure Connectivity Between Microsoft HealthVault and Physician Offices in Response to Consumer Demand
Kryptiq’s Connect IQ Secures Communication Between Patients and Healthcare Providers


09/26/2007
Opexa Therapeutics Appoints Dr. Dawn McGuire, Prominent Neurologist, to Multiple Sclerosis Clinical Advisory Board


09/19/2007
Kryptiq’s CareManager 3.3 Improves Chronic Care Management for Heart Failure, Osteoporosis Latest Version of Award-Winning Solution Addresses Continuing Demand in Provider Community


09/01/2007
For More Press Releases Please Visit www.opexatherapeutics.com

08/13/2007
Sapphire Therapeutics Announces Promotions and New Appointment to Management Team


07/10/2007
InterHospital Physician Association Implements Kryptiq’s Connect IQ™ Secure Messaging
One of the Largest and Oldest Independent Practice Associations Connects Providers Across Portland Community to Improve Care


06/20/2007
Kryptiq’s Choreo Contract Manager Implemented by Scott & White Health Plan
No. 1 Ranked Health Plan in Texas Committed to Setting the Standard for Healthcare Transparency


06/19/2007
Leading Health Plans Look to Kryptiq to Transform Provider Network Management
Company Unveils Customer Successes, Choreo 1.5 Suite, At AHIP Annual Meeting


06/18/2007
Kryptiq and Leading Health Plans Demonstrate Power of Choreo Suite at Institute 2007 – AHIPs Annual Meeting
Kryptiq to Highlight Success in Optimizing Provider Contract Management in Conjunction with The Regence Group and The TriZetto Group


06/05/2007
Leading Healthcare Provider Uses Kryptiq’s New Software Development Kits to Bridge Unconnected Enterprise Systems
MeritCare Health System Leverages Kryptiq SDKs to Improve Information Availability


06/04/2007
Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients With Refractory Non-Small Cell Lung Cancer Treated With Agennix's Oral Talactoferrin

Data from the Randomized, Double-Blind, Placebo-Controlled Phase II Trial Presented at ASCO


05/22/2007
Excellus BlueCross BlueShield Deploys Kryptiq’s Choreo to Standardize and Streamline Business Processes Across Complex Organization
Health Plan Improves Unification of Provider Contract Management Processes


05/22/2007
Kryptiq Partner Sage Software Recognized at TEPR Conference for Transforming Doctor/Patient Communications
Sage Software Healthcare, Inc. Wins Hot Product Award for Integration of Patient Portal with Intergy EHR using Kryptiq’s SDK


05/18/2007
2006 Practice of the Year Showcases How Kryptiq Solutions Solidify the Doctor-Patient Relationship
Kryptiq Customer, Family Medical Specialists of Texas, to Present with Physicians Practice at Annual TEPR Conference


05/17/2007
Kryptiq Launches Healthcare Leadership Series
Online Interviews Address Benefits and Challenges Facing Physicians as Practices Tackle Consumer Needs


05/16/2007
Kryptiq Announces Alliance with TriZetto for Enhanced Provider Network Management
Companies to Enable Health Plans to Create More Competitive Provider Networks


05/14/2007
e


05/08/2007
Kryptiq Announces Major OEM Agreement with GE Healthcare
Market Leader to Private-Label Industry Leading Connectivity Solutions


04/26/2007
Sapphire Therapeutics, Inc. to Present Results from Anamorelin Phase 2 Cachexia/Anorexia Studies at ASCO and ENDO Annual Meetings in June Ono Plans Japanese Phase 1 Stud


04/20/2007
Kryptiq CEO to Speak at Upcoming World Health Care Congress
Kryptiq’s Luis Machuca to join the President and CEO of Regence on Partnership for Workplace Wellness


03/20/2007
Houston Technology Center Announces $2 Million Award to PLx Pharma Inc., $794,520 Award to Molecular LogiX Inc. by the Texas Emerging Technology Fun


03/01/2007
Kryptiq Applauds Steps to Improve Healthcare Efficiency and Patient–Centered Care
Kryptiq Supports Congressman Patrick Kennedy’s Bill to Advance Efficiency and Effectiveness of Physician to Patient Relationship


02/26/2007
Kryptiq Unveils New Tools for Secure Healthcare Communication and Online Patient Services
New SDKs for CareCatalyst™ and Kryptiq Gateway™ Enable Organizations to Add Connectivity Quickly and Easily


02/20/2007
Regence Selects Kryptiq to Streamline and Simplify Provider and Facility Contract Management
Four-State Blues Plan Taps Choreo Contract Manager To Align Contracting Process With IT Strategy


02/08/2007
Regence BlueCross BlueShield Clinical Improvement Grant Fuels Deployment of Provider-Based Disease Management System from Kryptiq
Family Physician Group Selects CareManager to Fight Diabetes Epidemic


12/31/2006
For Additional Press Releases, Please Visit WWW.KRYPTIQ.COM


10/26/2006
Sapphire Therapeutics, Inc. Licenses Novel Drug to Ono Pharmaceuticals in Japan, Korea and Taiwan for the Treatment of Cancer Anorexia/Cachexi


10/12/2006
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma


10/05/2006
Agennix Receives FDA Fast Track Designation for Talactoferrin Alfa in Non-Small Cell Lung Cancer and Diabetic Foot Ulcer


09/19/2006
Sapphire Therapeutics, Inc. Licenses Ghrelin Mimetic From Novo Nordisk
Ipamorelin to Enter Phase II for Postoperative Ileus


08/25/2006
Sapphire Therapeutics, Inc. Expands Drug Development Team; New CEO, Board Appointment


01/17/2006
Sapphire Therapeutics, Inc. Appoints New Director and Scientific Advisory Board to Support Oncologic and Metabolic Pipeline Development


01/06/2006
Sapphire Therapeutics, Inc. Builds Drug Development Team Through New Hires and Promotion


12/15/2005
Sapphire Therapeutics, Inc.’s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia


11/30/2005
[KUHF] New Grant for Nano-Technology Cancer Research (by Laurie Johnson)


10/18/2005
Wallstreet Reporter Interviews Sapphire Therapeutics


10/05/2005
Rejuvenon Corporation. changes name to Sapphire Therapeutics; Closes on second tranche of Series B financing


09/29/2005
Fairway Medical Technologies Receives $2.9 Million National Cancer Institute Nanotechnology Grant for Early Breast Cancer Detection Technology


09/29/2005
[Houston Business Journal] Fairway gets grant for development of breast cancer technology


07/20/2005
Rejuvenon’s RC-8800 for Prostate Cancer Enters Human Testing
RC-1291 Ghrelin Mimetic Starts Phase II in Cachexia


06/14/2005
Biopharma Agennix To Seek Up To $50M For Phase III Trials


06/13/2005
Agennix's Topical Talactoferrin Improved Healing of Diabetic Ulcers


05/17/2005
Agennix's Oral Talactoferrin Improved Response Rates, Time to Progression and Duration of Response When Combined with First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer Presented at AAdvanced Non-Small Cell Lung Cancer


04/19/2005
Agennix's Oral Talactoferrin Substantially Improved Response Rates When Combined with First-Line Chemotherapy in Advanced Non-Small Cell Lung Caner


03/30/2005
Agennix Raises $22 Million in Private Financing


01/10/2005
Rejuvenon’s RC-1291 Ghrelin Mimetic Receives Fast Track Designation from FDA for Cancer Anorexia/Cachexia


12/09/2004
BCM Technologies names two new directors to the Board, James Hackett and Alan Buckwalter


09/28/2004
Fairway Medical Technologies, Inc. Expands Facilities


08/30/2004
Fairway Medical Technologies receives a major grant to study breast cancer


08/18/2004
Agennix Data Published in the International Journal of Cancer


06/23/2004
Rejuvenon Raises $37 Million in Series B Venture Financing; New Board Members Names


06/09/2004
VAMC and Agennix Release Lactoferrin Cancer Trial Results at ASCO


05/25/2004
Agennix Receives SBIR Asthma Funding, Presents at ATS Meeting


03/30/2004
Agennix Presents Positive RhLF Cancer Results at AACR Meeting


03/09/2004
Agennix Composition of Matter Patent on Recombinant Human Lactoferrin Upheld in Europe


09/17/2003
Agennix Inc. Receives $850,000 NIH Funding to Support Clinical Trials of rhLF Gel for Treatment of Patients with Diabetic Foot Ulcers


06/30/2003
Agennix appoints Dr. Frank Young Chairman of its Board of Directors


06/18/2003
Agennix Inc. Presents Positive Results Showing Accelerated Wound Healing and Wound Closure with Topical Recombinant Human Lactoferrin


05/22/2003
VAMC and Agennix Successfully Complete Safety Phase of Lactoferrin Cancer Trial


09/17/2002
Agennix and DSM Pharmaceutical Products announce opening of recombinant human lactoferrin manufacturing facility


05/29/2002
Agennix Completes $20 Million Private Placement Financing


05/14/2001
Dr. Waun Ki Hong, head of M.D. Anderson's Division of Cancer Medicine joins Agennix's Scientific Advisory


05/10/2001
Agennix Receives Broad Patent Covering Production of Human Lactoferrin in Eukaryotic Cell